REDWOOD CITY, Calif., June 14, 2016 (GLOBE NEWSWIRE) --
WHO: Biotricity, Inc. (OTCQB:BTCY), a healthcare technology company dedicated to delivering innovative, medically relevant biometric remote monitoring solutions, will present a comprehensive presentation at the Wearable Technologies Conference 2016 USA on July 12-13, 2016 in San Francisco, CA.
WHAT: There is significant dialogue around wearables, including their potential to revolutionize healthcare and the way we live. Wearables have the potential to enhance the healthcare system by aiding in the monitoring of patients, provide real-time access to health records, assist in medical procedures and provide quicker diagnosis and treatment of conditions.
In this presentation, Waqaas Al-Siddiq, Co-founder and CEO of Biotricity will discuss the company’s ground-breaking, clinical-grade, remote biometric monitoring solutions. Biotricity’s products are designed for both the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. The company’s flagship product (currently in development), is a mobile cardiac telemetry (MCT) solution that is designed to enable physicians to remotely monitor and diagnose cardiovascular disease (CVD) and coronary heart disease by detecting arrhythmias.
WHY: The benefits of utilizing wearable technology extend far beyond the healthcare system, as patients are given the opportunity to self-monitor their own health. Industry predictions indicate that the wearable medical devices market will reach $41.3 billion by 2020. Despite this promise, the steps taken towards application and integration into healthcare have been limited.
WHEN: The Wearable Technologies Conference 2016 USA opens on July 12-13, 2016 and is being held at the Fort Mason Center in San Francisco.
About Biotricity Inc.
Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
Media Contacts McCoin & Smith Communications Inc. Chris McCoin, Chris@mccoinsmith.com, 508-429-5988 Richard Smith, email@example.com, 978-433-3304 Investor Relations: Michael Koehler Liolios Group, Inc. BTCY@liolios.com, 949-574-3860